Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.91 USD
-0.07 (-6.68%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.92 +0.01 (1.10%) 5:20 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Brokerage Reports
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 281 - 300 ( 323 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CROI Data Could Be A Prelude To Positive Preliminary Phase 2 HIV Results At ASGCT In May; Increasing FV To $13 For HIV Progress And Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials Reaffirm Extended Cash Runway; Next: Transforming HIV Program Clinical Catalysts In H1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disruptive In Vivo Protein Replacement Platform Could Reduce ERT Costs For Monogenic Diseases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Were Uneventful; Cash Runway Covers Multiple Catalysts; Reiterate OUTPERFORM And $9 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Presented At Society for Neuroscience Provides Novel Mechanism For Treating Huntington''s Disease;
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences MAC Best Ideas Conference - New York City - August 14 & 15, 2012 Day 1 Key Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials Were Uneventful; Cash Runway Covers Multiple Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials Were Uneventful and There Is Plenty of Cash to Cover Multiple Transforming Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Publication of Preclinical Data Highlights Advantages of ZFN-Based Approach to Cancer Immunotherapy. Reiterate OUTPERFORM and $9 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CROI Clinical Data Continue To Suggest Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2011 Financials Were Uneventful: We See Significant Progress on the HIV Program in 2012 With Cash Runway for Several Years. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Semiconductor Industry Association (SIA) December Data: Revenue Increases M/M
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corporate Update: First Therapeutic Partnership Announced. Reiterate OUTPERFORM and $9 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2012 Could Be Transformational With HIV Phase 2 Data and the First Therapeutic Partnership.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Presented at ASH Shows Potential for ZFP Approach to Treating Hemophilia and Leukemia. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials: We See Significant Progress on the HIV Program in 2012 with Cash Runway Well Into 2013. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L